Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
380 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03721172 | Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy(ADVANCE) | completed | Phase 3 | 595 | AmgenINDUSTRY | 2 | May 29, 2024 | clinicaltrials |
| NCT02000427 | Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia | completed | Phase 2 | 45 | AmgenINDUSTRY | 5 | May 28, 2024 | clinicaltrials |
| NCT03301857 | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | completed | Phase 4 | 85 | AmgenINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | completed | Phase 1 / Phase 2 | 217 | AmgenINDUSTRY | 3 | May 14, 2024 | clinicaltrials |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | completed | Phase 1 | 36 | AmgenINDUSTRY | 6 | May 14, 2024 | clinicaltrials |
| NCT02187354 | Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL(RIALTO) | no longer available | — | — | AmgenINDUSTRY | 7 | May 13, 2024 | clinicaltrials |
| NCT02792478 | Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study(PERSEIDA) | completed | — | 238 | AmgenINDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT04524455 | Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | completed | Phase 1 | 17 | AmgenINDUSTRY | 9 | Apr 8, 2024 | clinicaltrials |
| NCT04478695 | Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 1 | AmgenINDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02013167 | Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 3 | 405 | AmgenINDUSTRY | 21 | Mar 5, 2024 | clinicaltrials |
| NCT02756845 | Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors | completed | Phase 1 | 15 | AmgenINDUSTRY | 7 | Feb 20, 2024 | clinicaltrials |
| NCT05073315 | A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis | completed | Phase 3 | 425 | AmgenINDUSTRY | 6 | Feb 9, 2024 | clinicaltrials |
| NCT02561962 | A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 42 | AmgenINDUSTRY | 2 | Feb 1, 2024 | clinicaltrials |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) | terminated | Early Phase 1 | 46 | AmgenINDUSTRY | 3 | Sep 1, 2023 | clinicaltrials |
| NCT05045638 | Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants | completed | Phase 1 | 13 | AmgenINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03064763 | Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma | completed | Phase 1 | 18 | AmgenINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT00556374 | Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | completed | Phase 3 | 3,420 | AmgenINDUSTRY | 2 | Jul 27, 2023 | clinicaltrials |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | AmgenINDUSTRY | 0 | Jul 3, 2023 | clinicaltrials |
| NCT01967160 | Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid | completed | — | 2,560 | AmgenINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05913115 | A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer | completed | Phase 1 | 6 | AmgenINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03904069 | Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02211131 | Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma | completed | Phase 2 | 150 | AmgenINDUSTRY | 9 | Jun 5, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT03476239 | Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 121 | AmgenINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02412306 | Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 66 | AmgenINDUSTRY | 1 | Dec 12, 2022 | clinicaltrials |
| NCT03091127 | Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe | completed | — | 705 | AmgenINDUSTRY | 11 | Dec 12, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT01752907 | Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim(VINE) | completed | Phase 2 | 304 | AmgenINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 | clinicaltrials |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 22 | AmgenINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT00321464 | A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. | completed | Phase 3 | 2,049 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 65 | AmgenINDUSTRY | 3 | Nov 8, 2022 | clinicaltrials |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | completed | Phase 3 | 1,718 | AmgenINDUSTRY | 29 | Nov 8, 2022 | clinicaltrials |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 210 | AmgenINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01732783 | Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients | completed | — | 213 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT00089635 | Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 203 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT00113763 | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 463 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT00330759 | Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. | completed | Phase 3 | 1,779 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT00364013 | PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | completed | Phase 3 | 1,183 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT01253707 | A Study of AMG 337 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 111 | AmgenINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02003612 | Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia | completed | — | 2,373 | AmgenINDUSTRY | 8 | Nov 7, 2022 | clinicaltrials |
| NCT00446446 | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | completed | Phase 2 | 52 | AmgenINDUSTRY | 0 | Oct 5, 2022 | clinicaltrials |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ProxiMMity-1) | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 0 | Sep 27, 2022 | clinicaltrials |
| NCT00339183 | Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | completed | Phase 3 | 1,186 | AmgenINDUSTRY | 0 | Sep 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials